Latest quarter
Leidos reported third-quarter revenue of $4.6 billion, up from $4.5 billion a year earlier but below the consensus estimate of $4.71 billion. Diluted earnings per share rose to $3.28 from $2.82; on a non-GAAP basis, the company reported $3.62, up 19% from a year earlier.
CFO Chris said Homeland revenue grew 32% in total and 15% organically, supported by demand for domestic and international air traffic management. He said the health segment contracted because of changes to the veterans’ disability-exam business, while intelligence and digital revenue grew 1% as intelligence demand offset reductions in some federal civilian IT programs.
Leidos reported a gross margin of 17.7%, compared with 18.4% a year earlier, and an operating margin of 11.9%, compared with 12.0%. Chris said the company generated $523 million in operating cash flow and $476 million in free cash flow during the quarter. The filing attributed the year-over-year decline in operating cash flow to working-capital changes, including the timing of vendor, payroll and employee benefit payments.
| Q3 FY2026 | Q3 FY2025 | Change | |
|---|---|---|---|
| Revenue | $4.6 billion | $4.5 billion | 3.60% |
| Diluted EPS | $3.28 | $2.82 | 16.3% |
| Gross margin | 17.7% | 18.4% | −0.7 percentage points |
| Operating margin | 11.9% | 12.0% | 0.0 percentage points |
| Free cash flow | $765.0 million | $457.0 million | 67.4% |
| Against the consensus | Reported | Consensus | Result |
|---|---|---|---|
| Adjusted EPS | $3.26 | $2.90 | Beat by 12.4% |
| Revenue | $4.6 billion | $4.4 billion | Beat by 4.50% |
Adjusted EPS is the figure the consensus estimates, not the GAAP EPS above.
What management said on the call
CEO Tom Bell said customers were beginning to move faster on procurement decisions, although some decisions continued to slip. He pointed to total backlog of $49.6 billion and funded backlog of $11.1 billion, the latter up 22% year over year. Bell said backlog was a more useful measure of sustained growth than quarterly book-to-bill, which he described as episodic.
On defense, Bell said more than a dozen programs were moving from development into rate production. He said Leidos had secured more than $10 billion in defense technology awards over the preceding 18 months and $6 billion year to date. CFO Chris said fourth-quarter capital spending should rise from the third quarter, primarily to add defense technology production capacity.
Chris attributed the quarter’s health contraction to changes in the veterans’ disability-exam contract. He said company-wide cost controls supported margins and earnings, while putting downward pressure on growth from cost-plus contracts. He also said favorable contract estimate adjustments contributed to the quarter’s margins and that Leidos was not assuming the same level in the fourth quarter.
Asked about the competition for the veterans’ exam work, Bell said the request for proposals remained in draft and that he expected existing contracts to be extended through the first half of 2027. He said the draft recognized demonstrated performance and contemplated allocating more work to providers based on delivery. Chris said it was too early to commit to an expectation that Leidos would receive more work under the future contract.
Bell also said Leidos had not been selected in the initial round of a maritime vessel program but was pursuing other customer engagements. For the quarter ahead, Chris said some booking delays and decisions that went against Leidos would temper growth in the fourth quarter and into 2027.
Guidance
Leidos raised its FY2026 non-GAAP diluted EPS range to $12.50–$12.70 from $12.20–$12.50. It also raised its operating cash flow guidance to nearly $1.9 billion from $1.85 billion.
CFO Chris said the updated outlook reflected the divestiture of the security enterprise solutions business. He said its previously forecast fourth-quarter revenue of approximately $200 million was reflected in the new revenue guidance range.
| Metric | For | Guide | Previous guide | Change |
|---|---|---|---|---|
| Revenue, Excluding Health | FY2027 | Leidos expects above-market revenue growth across its portfolio excluding health in 2027. | — | — |
| Revenue, Energy | FY2027 | Leidos expects double-digit growth in its energy business in 2027. | — | — |
| Net income | FY2027 | Leidos does not expect bottom-line growth in 2027. | — | — |
| Revenue, Defense | Q4 FY2026 | Leidos expects a higher defense revenue growth rate in the fourth quarter. | — | — |
| Operating margin, Defense | FY2027 | Leidos expects its defense segment margin to rise in 2027. | — | — |
| Operating margin, Health | Q4 FY2026 | Leidos expects its health segment margin to be in the high teens in the fourth quarter. | — | — |
| Revenue | Q4 FY2026 | Leidos expects fourth-quarter revenue to be near third-quarter levels. | — | — |
| Tax rate, non-GAAP | FY2026 | 20.0% | — | New |
| Units, Diluted Shares | FY2026 | 126,000,000 | — | — |
| EBITDA, non-GAAP | FY2026 | Leidos expects its adjusted EBITDA margin to remain in the mid-13s for 2026. | — | — |
| Capex | Q4 FY2026 | Leidos expects fourth-quarter capital expenditures to step up from the third quarter. | — | — |
| EPS, non-GAAP | FY2026 | $12.50–$12.70 | $12.20–$12.50 | Raised |
| EBITDA growth, non-GAAP | FY2026 | 13.0% | — | New |
| Operating cash flow | FY2026 | $50.0 million | $1.8 billion | Cut |
| Revenue | FY2026 | $200.0 million | $18.0 billion–$18.4 billion | Cut |
| Operating margin, Health | FY2026 | 20.0% | — | New |
| Revenue growth, Excluding Health | FY2026 | 7.00% | — | New |
| EBITDA growth | FY2026 | 13.0% | — | New |
| Capex | FY2026 | $250.0 million | — | New |
| Operating margin, Health | Long term | 20.0% | — | New |
| EPS | FY2026 | $12.10–$12.50 | — | New |